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Breast cancer is the most common malignancy in women. A
family history of breast cancer has long been recognized as one of
the strongest risk factors for the disease and it is estimated that
5–10% of all breast cancer cases can be attributed to inherited
autosomal dominant susceptibility genes. Two genes involved in
hereditary breast and/or ovarian cancer syndromes, BRCA1 and
BRCA2, were cloned (Miki et al, 1994; Wooster et al, 1995;
Tavtigian et al, 1996). Initially, reports on extended high-risk fami-
lies suggested that germline mutations in BRCA1 would account
for about 45% of the hereditary site-specific breast cancer fami-
lies, and for more than 80% of the hereditary breast and ovarian
cancer families (Easton et al, 1993). Similar studies predicted the
involvement of BRCA2 in the majority of non-BRCA1-linked
breast cancer families (Wooster et al, 1994). Recent studies,
however, show that germline mutations in BRCA1 and BRCA2 are
only associated with approximately half of all hereditary breast
and/or ovarian cancer, and that this proportion varies widely
among populations (for review see Szabo and King, 1997).
Most of our current knowledge on genetic predisposition by
BRCA1 or BRCA2 is based on families with multiple cases of
breast and/or ovarian cancer. Few data are available on less
extended families, i.e. with only three to five individuals with
breast and/or ovarian cancer, although they form the majority of
families seeking genetic advice in the family cancer clinics.
In this study we determined the frequency of both BRCA1 and
BRCA2 germline mutations in relatively small families whose
cancer risk was evaluated at our family cancer clinics. Striking
differences in the prevalence of BRCA1 or BRCA2 mutations were
found in families with only breast cancer when families were clas-
sified according to the presence or absence of bilateral breast
cancer and the age of diagnosis of the youngest patient.
MATERIALS AND METHODS
Study population
Self-referred or physician-referred breast and/or ovarian cancer-
prone families visiting the family cancer clinics at The University
Hospital Nijmegen and The Netherlands Cancer Institute were the
subjects of this study. For the categorization of the families, first-,
second- and third-degree relatives of the person tested were taken
into consideration. The number of affected individuals varied
between three and nine (mean 4.3; median 4) in families with at
least one case of ovarian cancer and between three and five (mean
of 3.6; median 3) in families without ovarian cancer. If possible,
the patients with the highest prior probability of carrying a muta-
tion in one of the susceptibility genes were examined. In 93 fami-
lies one or more patients with a history of breast and/or ovarian
cancer were investigated. In 11 families only unaffected first-
degree relatives could be sampled for various reasons. On average,
1.4 individuals were tested in each family. For most patients 
clinical archives and pathological records were retrieved and 
Characteristics of small breast and/or ovarian cancer
families with germline mutations in BRCA1 and BRCA2
MJL Ligtenberg1,2, FBL Hogervorst3, HW Willems2, PJW Arts1, G Brink3, S Hageman3, EAJ Bosgoed1,
E Van der Looij1, MA Rookus4, P Devilee5, EMAW Vos3, G Wigbout3, PM Struycken3, FH Menko3,6, EJTh Rutgers3,
EH Hoefsloot1, ECM Mariman1, HG Brunner1 and LJ Van’t Veer3
Departments of 1Human Genetics and 2Pathology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands; 3Department of Pathology
and The Family Cancer Clinic, and 4Department of Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands;
5Department of Human Genetics and Department of Pathology, University of Leiden, PO Box 9503, 2300 RA Leiden, The Netherlands; 6Family Cancer Clinic,
Department of Clinical Genetics, University Hospital Vrije Universiteit, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Summary For families with a small number of cases of breast and/or ovarian cancer, limited data are available to predict the likelihood of
genetic predisposition due to mutations in BRCA1 or BRCA2. In 104 families with three or more affected individuals (average 3.8) seeking
counselling at family cancer clinics, mutation analysis was performed in the open reading frame of BRCA1 and BRCA2 by the protein
truncation test and mutation-specific assays. In 31 of the 104 families tested, mutations were detected (30%). The majority of these mutations
(25) occurred in BRCA1. Mutations were detected in 15 out of 25 families (60%) with both breast and ovarian cancer and in 16 out of 79
families (20%) with exclusively cases of breast cancer. Thus, an ovarian cancer case strongly predicted finding a mutation (P < 0.001). Within
the group of small breast-cancer-only families, a bilateral breast cancer case or a unilateral breast cancer case diagnosed before age 40
independently predicted finding a BRCA1 or BRCA2 mutation (P = 0.005 and P = 0.02, respectively). Therefore, even small breast/ovarian
cancer families with at least one case of ovarian cancer, bilateral breast cancer, or a case of breast cancer diagnosed before age 40, should
be referred for mutation screening.
Keywords: breast cancer; ovarian cancer; bilateral breast cancer; BRCA1; BRCA2
1475
British Journal of Cancer (1999) 79(9/10), 1475–1478
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0235
Received 19 May 1998
Revised 7 August 1998
Accepted 20 August 1998
Correspondence to: MJL Ligtenberg, Department of Human Genetics,
University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen,
The Netherlandsre-evaluated. All analyses were performed after pretest coun-
selling and after informed consent had been obtained.
Mutation detection in BRCA1 and BRCA2
Both labs performed the complete mutation screening for the fami-
lies referred to their clinics. Isolation of DNA and RNA from
EDTA blood and generation of polymerase chain reaction (PCR)
and nested reverse transcription (RT)-PCR products were
performed using standard procedures. Primers, containing a T7
promoter, a eukaryotic translation initiation sequence and gene-
specific sequences, were used to generate PCR products suitable
for analysis by the protein truncation test (PTT). PCR products
were in vitro transcribed and translated in the TNT/T7 coupled
reticulolysate system (Promega), essentially as described by the
manufacturer.  35S-methionine (NKI/AvL lab) or biotinylated
tRNA-Lysine (tRNA-scend, Promega) (Nijmegen lab) were used
to label de novo synthesized proteins.
For PTT analysis of BRCA1, five or six overlapping fragments
covering the entire open reading frame were amplified essentially
as described before (Hogervorst et al, 1995). The 5¢ and 3¢ coding
exons (exons 2, 3, 5, 6, 23 and 24) as well as exon 20 were
screened by the Nijmegen laboratory for the presence of frame-
shift mutations in multiplex PCRs using fluorescently labelled
primers annealing in the surrounding introns. The Netherlands
Cancer Institute laboratory screened for the 185delAG recurrent
mutation in exon 2 by single base sequencing. The frequently
occurring deletions of exon 13 and 22 were determined by PCR
analysis of genomic DNA essentially as described (Petrij-Bosch et
al, 1997).
For the BRCA2 mutation analysis by PTT, nine overlapping
fragments encompassing the entire open reading frame were
designed. Four primer sets were used to amplify exon 11 from
genomic DNA (fragments C, D, E and F). The remaining frag-
ments (two fragments (A and B) upstream and including the 5¢
region of exon 11, three fragments (G, H, K) downstream and
including the 3¢ region of exon 11) were amplified from cDNA by
nested PCR. PTT analysis of fragment H (encompassing exons
15–23) failed for most patients. In about 10% of individuals the
interpretation of the PTT of fragment K (exons 19–27) was
complicated due to the insertion of an alternatively spliced exon
(exon 20b), which generates a frame-shift and a premature stop
(data not shown). As a control for the PTT on RT-PCR products,
an additional primer set was designed to analyse exon 10 from
genomic DNA by PTT (all primer sequences are available upon
request).
Direct sequence analysis
Direct sequence analysis was performed using the dye primer or
the  Taq DyeDeoxy terminator cycle sequencing kit (Applied
Biosystems and Perkin Elmer) according to the manufacturer. The
sequence reactions were run and analysed using an automatic
sequencer (ABI 373A).
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Table 1 BRCA1 and BRCA2 mutations
Mutation Change No. of families
BRCA1
185delAG stop 39 1
1438delT stop 440 1
2312del5 stop 736 6
2804delAA stop 901 5
3109insAA stop 999 1
3604delA stop 1209 2
3867G->T E1250X 2
IVS21-36 del510 (del exon 22) stop 1803 8
BRCA2
690delAA stop 157 1
5823delAT stop 1874 1
6174delT stop 2003 1
6503delTT stop 2099 2
Table 2 Predictive factors of finding a BRCA1 or BRCA2 mutation in small families with breast and/or ovarian cancer
Type of family No. of No. of BRCA1 No. of BRCA2 Total no. of Test of the factor
families mutations mutations mutations predicting mutation
statusa (P-value)
Univariate Multivariate
model model
Total group 104 26 5 31 (30%)
Only breast cancer 79 11 5 16 (20%)
Breast and ovarian cancer 25 15 0 15 (60%) < 0.001 < 0.001
Breast and ovarian cancerb
³ 2 breast with 1 ovarian 14 8 0 8 (57%)
³ 1 breast with 2 ovarian 11 7 0 7 (64%) = 0.806
Only breast cancerc
No bilateral 43 2 1 3 (7%)
³ 1 bilateral 36 9 4 13 (36%) = 0.004 = 0.005
No patient < 40 years 33 0 2 2 (6%)
³ 1 patient < 40 years 46 11 3 14 (30%) = 0.016 = 0.020
< 3 patients < 50 years 45 2 4 6 (13%)
³ 3 patients < 50 years 34 9 1 10 (29%) = 0.085 = 0.863
aP-value of the b-coefficient of the factor in a logistic model with mutation status as the dependent variable: the multivariate models include (1) the presence of
ovarian cancer, ³ 1 bilateral cancer and ³ 1 breast or ovarian cancer below age 40, for the total group; and (2) the three factors listed for the group with only
breast cancer. bAt least 3 cases/family, mean 4.3 cases/family, median 4 cases. cA total of 3–5 cases/family, mean 3.6 cases/family, median 3 cases.Statistical analysis
In order to predict the finding of a BRCA1 or BRCA2 mutation,
logistic models were fitted with mutation status as the dependent
variable and the various family cancer histories as potential
predicting factors. In multivariate models we investigated mutual
dependency of the predicting factors. The reported P-values for the
tests of significance of the regression coefficients are two-sided.
RESULTS
Mutation analysis of BRCA1 and BRCA2
In individuals from 104 families with at least three members
affected with breast and/or ovarian cancer, the open reading
frames of BRCA1 and BRCA2 were screened for mutations. In 26
families a mutation in BRCA1 and in five families a mutation in
BRCA2 was detected. All mutations are listed in Table 1.
Classification of families and variables predicting their
mutation frequencies
To analyse in which kinds of families the mutations were found, all
families were first categorized according to the presence or
absence of one or more cases of ovarian cancer (Table 2). In 15 out
of 25 families (60%) with at least one case of ovarian cancer, a
mutation was detected. In 20% (16/79) of the families with three to
five cases of breast cancer without ovarian cancer a mutation was
found. For the total group the presence of ovarian cancer strongly
predicted mutation status (univariate and multivariate P < 0.001;
Table 2). Among families with ovarian cancer the number of
ovarian cancer cases (one or more) was not predictive, but the
subgroups were rather small (P = 0.806; Table 2). The proportion
of mutation-positive families was similar for families with three
affected cases (14/49, 29%) as compared to families with more
cases (17/55, 31%; P = 0.795; data not shown).
The families without a case of ovarian cancer, the so-called
‘breast-cancer-only’ families, were classified according to the
presence of bilateral breast cancer, the presence of at least one case
diagnosed before age 40, or the number of patients diagnosed
before age 50. Table 2 shows that the probability of finding a
mutation was markedly higher in the families with at least one case
of bilateral breast cancer (36%) than in families with only unilat-
eral breast cancer (7%) (P = 0.004). Also, the presence of at least
one breast cancer case before age 40 strongly predicted finding a
BRCA1 or BRCA2 mutation within these breast-cancer-only fami-
lies. A mutation was found in 30% of the families with such a case
and in only 6% of the remaining families (P = 0.016). The number
of cases diagnosed before age 50 was less predictive for mutation
status (P = 0.085; Table 2).
The presence of a bilateral case, and the presence of a case
younger than 40, proved to be independent predicting factors in the
multivariate model (P = 0.005 and P = 0.020, respectively; Table
2), which means that within families with a bilateral breast cancer
case, the probability of finding a mutation was even higher if at
least one case was diagnosed before age 40. Table 3 shows that a
mutation was found in 11 out of 23 such families (48%). In
contrast, in all 20 families with exclusively unilateral breast cancer
diagnosed after age 40, no mutation was found.
DISCUSSION
Since the cloning of BRCA1 and BRCA2 it has become possible to
offer women DNA tests for the two most common breast cancer
susceptibility genes without depending on linkage analyses. The
present study provides insight into the frequency of BRCA1 and
BRCA2 mutations in relatively small cancer-prone families. We
observed that most mutation-positive families share specific char-
acteristics.
More than 90% of the mutations in BRCA1 and BRCA2 reported to
the Breast Cancer Information Core electronic database (internet
address:http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/
Bic/) should be detectable by the techniques used here. Thirty-one
families (30%) were shown to have a germline mutation, either in
BRCA1 or BRCA2. All eight different BRCA1 mutations have been
found more than once, either in our study group or in other Dutch
families (Hogervorst et al, 1995; Peelen et al, 1997; Petrij-Bosch et
al, 1997), supporting the observation of strong founder effects in the
Dutch population.
In 60% of families with at least one case of ovarian cancer, a
mutation was found, showing that in small families the presence of
ovarian cancer in combination with a family cancer history is a
good indication for genetic predisposition. Our study confirms that
the presence of a BRCA1 mutation confers a high risk of devel-
oping ovarian cancer, since this cancer was present in 58% of the
families with a BRCA1 mutation.
In families without ovarian cancer, we found that the presence of
at least one breast cancer case diagnosed before age 40 and the
presence of one bilateral breast cancer case, are strong independent
predicting factors for the presence of a mutation in BRCA1 or
BRCA2 (Tables 2 and 3). A study on the frequency of BRCA1 muta-
tions only in a group of 798 persons at elevated risk of hereditary
breast/ovarian cancer showed that the probability of having a
BRCA1 mutation is increased when the index patient has bilateral
breast cancer in comparison to an index patient with unilateral
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Table 3 Characteristics of families with three to five cases of breast cancer without ovarian cancer
Type of breast-cancer-only family No. of No. of BRCA1 No. of BRCA2 Total no. of
families mutations mutations mutations
No bilateral breast cancer
No patient < 40 years 20 0 0 0 (0%)
³ 1 patient < 40 years 23 2 1 3 (14%)
At least one bilateral breast cancer
No patient < 40 years 13 0 2 2 (14%)
³ 1 patient < 40 years 23 9 2 11 (48%)breast cancer (Shattuck-Eidens et al, 1997). The predictive value of
bilateral breast cancer was not noted in another set of small families
(Couch et al, 1997). However, this discrepancy may be due to their
inclusion of families with ovarian cancer in all analyses.
More than twice as many BRCA1 as BRCA2 mutations were
found in families with exclusively breast cancer. However, in
families with an age at diagnosis of the youngest patient of over 40
years, only BRCA2 mutations were detected. These data support
the theory that BRCA2 mutations are an infrequent cause of early-
onset breast cancer (Krainer et al, 1997), but that they are still of
importance in familial late-onset breast cancer.
In the families in which no mutation was found, either a muta-
tion in BRCA1 and BRCA2 that is not detectable by the techniques
used (e.g. large genomic deletions, promoter or missense muta-
tions) might still be present, a genetic susceptibility caused by
mutations in another thus far unidentified gene might be present,
or the clustering of breast and/or ovarian cancer might have
occurred by chance.
The results of the screening for BRCA1 and BRCA2 mutations
in 104 families indicate that there is a considerable risk of genetic
predisposition in those small families with at least one case of
ovarian cancer, bilateral breast cancer, or a case of breast cancer
diagnosed before age 40. Therefore, even small breast cancer
families with these characteristics should be referred for BRCA1
and BRCA2 mutation testing.
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